High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events

It is unclear whether the ChAdOx1 nCov-19 vaccine can induce the development of anti-PF4 antibodies in vaccinated individuals who have not developed thrombosis. The aim of this prospective study was to evaluate the presence of antibodies against heparin/PF4 in adults who received a first dose of the...

Full description

Bibliographic Details
Main Authors: Evangelos Terpos, Marianna Politou, Ioannis Ntanasis-Stathopoulos, Vangelis Karalis, Efrosyni Merkouri, Despina Fotiou, Maria Gavriatopoulou, Panagiotis Malandrakis, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A. Dimopoulos
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Vaccines
Subjects:
SARS-CoV-2
COVID-19
ChAdOx1 nCov-19
anti-PF4
antibodies
vaccine
Online Access:https://www.mdpi.com/2076-393X/9/7/712

Internet

https://www.mdpi.com/2076-393X/9/7/712

Similar Items